The 3rd edition of the Kisaco Research international Phage Futures Congress will be held as a Virtual summit from Wednesday 24th February till Friday 26th February 2021.
What is the 3rd Phage Futures Congress and Why attend?
The market of phage applications has been growing in both investments and innovations. New opportunities for revenue are being explored for both preventative treatments as well as therapeutics. Phage application has also shown an increased interest in other industries, such as; animal health, biocontrol, and manipulating the microbiome for the targeting of chronic conditions including; cancer, acne, asthma, and Inflammatory Bowel Diseases.
The 3rd edition of the Phage Futures Congress will bring together individuals from a range of fields for 3 days, and industry leaders will be focusing on translating phage-based applications into clinically and commercially viable therapeutics. There is also content available on-demand which will be available 2 weeks prior to the event.
Who will be at the 3rd Phage Futures Congress?
Over 25 speakers from a diversity of fields will be attending.
The summit will bring together individuals from different industries and occupations, such as; academia, biotech, pharma, regulatory and governments, service providers, and clinicians.
Agenda for 3rd Phage Futures Congress 2021
Wednesday 24th February 2021
Dr. Richard Alm Director of Alliances, CARB-X & Consultant for WHO – Overview of the latest progressions in the clinical landscape for phage-based application
Dr. Todd Black Executive Director of Infectious Diseases at Merck & Co. and Dr. Henry ‘Chip’ Chambers Professor of Medicine at Emeritus in UC San Francisco & Principal Investigator at ARLG – Pharma Insights: Designing phage-based clinical trials to prove efficacy
Dr. Paul Turner Professor of Ecology & Evolutionary Biology at Yale University and Ella Balasa Patient Advocacy and Engagement Consultant – Phage Therapy for Treating Lung Infections
Dr. David Ousterout CSO & Co-Founder of Locus Biosciences – Phage Therapy for Urinary Tract Infections
Dr. Gina Suh Infectious Disease Specialist at Mayo Clinic – Phage Therapy for Prosthetic Joint Infections
Dr. Mimi Yen CEO & Co-Founder of PhagePro and Dr. Tobi Nagel Founder of Phages for Global Health – Phage Therapy for Preventing & Treating Diseases in Developing Countries
Dr. Biswajit Biswas Chief of Phage Laboratory of Biological Defense Research Directorate at US Naval Medical Research Center – Phage Therapy for Wound Infections
Dr. Xavier Duportet CEO & Co-Founder of Eligo Biosciences – Precise manipulation of the microbiome composition via the delivery of CRISPR-Cas nuclease with phage-derived particles
Dr. Paul Turner Professor of Ecology & Evolutionary Biology at Yale University, Dr. Bob Blasdel Research Director at Vesale Pharma, and Professor Martha Clokie Professor of Microbiology at University of Leicester – Translating in vitro into in vivo: Understanding the pharmacology of bacteriophages
Dr. Frenk Smrekar CEO & Co-Founder of JAFRAL Ltd. and Dr. Barbara Hubad COO of JAFRAL Ltd. – From initial phage candidate to manufacturing Clinical Trial Material
Dr. Frenk Smrekar CEO & Co-Founder of JAFRAL Ltd., Dr. Nick Conley Principal Scientist at Locus Bioscience, and Dr. Michael Koeris Portfolio Executive at the NIH RADx COVID-19 Response Program at NIH – To Build or To Buy: In-house or Out-source?
Dr. Adam Ostrowski Technical Applications Specialist at Cellexus – Beyond the flask: phage amplification at scale
Dr. Timothy Lu Associate Professor of Biological Engineering at the Synthetic Biology Center at MIT and Dr. Steven Theirault CEO of Cytophage – Programming Specificity with Synthetic Phages
Dr. Danish Malik Reader in Industrial Biotechnology at Loughborough University – Considerations for liquid formulations & solid dosage forms
Dr. David Pride Associate Director of Microbiology at UC San Diego – Sequencing in the phage-application space
Dr. Graham Hatfull Eberly Family Professor of Biotechnology, HHMI Professor at University of Pittsburgh – Phage Hunting: Collecting, identifying & characterizing phages
Thursday 25th February 2021
Dr. Michael Koeris Portfolio Executive at the NIH RADx COVID-19 Response Program at NIH and Dr. Carrie-Lynn Furr Co-Founder & CEO of Bacteriophage & Drug Development Consultants LLC – Creating a robust market infrastructure for phage therapy
Michael Higgins MD Biopharmaceuticals Equity Research at Ladenburg Thalmann, Dr. Joe Campbell Research Resources Project Officer at NIAID, NIH, Greg Merril CEO of Adaptive Phage Therapeutics, and Dr. Richard Alm Director of Alliances, CARB-X & Consultant for WHO – Securing financial support from the public, private & philanthropic sectors to continue innovation in phage-based applications
Dr. Sailaja Puttagunta CMO at BiomX – Phage Therapy for Inflammatory Bowel Disease & Primary Sclerosing Cholangitis
Dr. David Pride Associate Director of Microbiology at UC San Diego – The Role of the Virome in the Microbiome
Dr. Biswajit Biswas Chief of Phage Laboratory of Biological Defense Research Directorate at US Naval Medical Research Center and Dr. Subhendu Basu COO of Adaptive Phage Therapeutics – Phage-Based Vaccine Development Platforms
Anupuma Hoey CBO of Sensei Biotherapeutics – Phage-Based Vaccine Development in Oncology
Dr. Steven Theriault CEO & CSO of Cytophage Technologies – Synthetic Phages in Lifestock Health
Dr. Joël van Mierlo R&D Manager for Micreos Food Safety at Micreos – Phage Application in Food Safety
Dr. Benjamin Chan Associate Research Scientist at Yale University, Dr. Gina Suh Infectious Disease Specialist at Mayo Clinic, Dr. Graham Hatfull Eberly Family Professor of Biotechnology, HHMI Professor at the University of Pittsburgh, Dr. Jonathon Iredell Director of Centre for Infectious Diseases & Microbiology at Westmead Institute for Medical Research, and Dr. Shawna McCallin Clinical Coordinator at Balgrist University Hospital – Success or failure in compassionate use; why does phage therapy not always succeed?
Friday 26th February 2021
Dr. Carrie-Lynn Furr Co-founder & CEO of Bacteriophage & Drug Development Consultants LLC – Short discussion on the US Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act and its implications for phage therapy
Dr. Cara Fiore Microbiologist, Office of Vaccine Research & Review at FDA – International regulatory requirements for the approval of phage therapeutics
View past events by Kisaco Research